Anderson, Katherine M.
Blumenthal, Jill
Jain, Sonia
Sun, Xiaoying
Amico, K. Rivet
Landovitz, Raphael
Zachek, Christine M.
Morris, Sheldon
Moore, David J.
Stockman, Jamila K.
Funding for this research was provided by:
California HIV/AIDS Research Program (EI11-SD-005B, EI11-SD-005B, EI11-SD-005B, EI11-SD-005B, EI11-SD-005B, EI11-SD-005B, EI11-SD-005B, EI11-SD-005B)
National Institutes of Health (KL2TR001444)
Center for AIDS Research, University of California, San Diego (P30AI036214, P30AI036214, P30AI036214, P30AI036214, P30AI036214)
Article History
Received: 31 August 2023
Accepted: 23 May 2024
First Online: 31 May 2024
Declarations
:
: The research protocol was approved by the relevant Institutional Review Boards at University of California Los Angeles, Harbor-UCLA Medical Center, University of Southern California, and University of California San Diego. The study was registered at clinicaltrials.gov (NCT02584140) on 15/10/2015. All participants provided informed consent prior to study screening.
: N/A.
: KMA, SJ, XS, KRA, CZ, DM, and JKS have no competing interests to declare. JB reports research funding from Gilead Sciences outside of the submitted work. RL reports personal fees from Gilead Sciences and personal fees from Merck, outside the submitted work. SM reports research funding form Gilead Sciences and Merck, stock in Bristol Myers Squibb and Pfizer, and is a cofounder of Aspera Biomedicines.